Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures-Reference-Cited by-同舟云学术

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Published:2024-04-09 Issue:6 Volume:38 Page:1423-1426
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Zanwar Saurabh^ORCID,Gertz Morie A.^ORCID,Muchtar Eli^ORCID,Buadi Francis K.^ORCID,Kourelis Taxiarchis^ORCID,Gonsalves Wilson,Go Ronald S.^ORCID,Hayman Suzanne,Kapoor Prashant^ORCID,Binder Moritz^ORCID,Cook Joselle^ORCID,Dingli David^ORCID,Leung Nelson^ORCID,Lin Yi^ORCID,Warsame Rahma,Fonder Amie,Hobbs Miriam,Hwa Yi Lisa,Kyle Robert A.,Rajkumar S. Vincent^ORCID,Kumar Shaji^ORCID,Dispenzieri Angela^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02243-5.pdf

Reference15 articles.

1. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

2. Ravichandran S, Cohen OC, Law S, Foard D, Fontana M, Martinez-Naharro A, et al. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer J. 2021;11:118.

3. Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99:309–24.

4. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N. Engl J Med. 2021;385:46–58.

5. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–7.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis;European Journal of Haematology;2024-08-27

2. Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis;American Journal of Hematology;2024-08-03

3. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab;Current Oncology Reports;2024-06-19

4. Response matters in light chain amyloidosis, whatever it takes;British Journal of Haematology;2024-06-06